Odonate Therapeutics Inc
Change company Symbol lookup
Select an option...
ODT Odonate Therapeutics Inc
EQBK Equity Bancshares Inc
SMBK SmartFinancial Inc
FHN First Horizon Corp (Tennessee)
STAF Staffing 360 Solutions Inc
TEL TE Connectivity Ltd
BOKF BOK Financial Corp
PRAA PRA Group Inc
XEL Xcel Energy Inc
XEC Cimarex Energy Co

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).

Day's Change
0.1787 (5.38%)
B/A Size
Day's High
Day's Low
(Above Average)

Today's volume of 985,341 shares is on pace to be greater than ODT's 10-day average volume of 3,318,543 shares.


Upcoming Events

ODT's fiscal year ends in December
There are no upcoming events for ODT

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
estimate range
Previous year's
February 23, 2021Q4 2020 Earnings Release-$0.83-$1.01 to -$0.68-$0.90
October 28, 2020Q3 2020 Earnings Release-$0.93-$1.19 to -$0.66-$0.88
July 30, 2020Q2 2020 Earnings Release-$1.09-$1.11 to -$0.88-$1.15
April 28, 2020Q1 2020 Earnings Release-$0.99-$1.09 to -$0.90-$1.16

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.